Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.46 USD

26.46
1,365,663

+0.15 (0.57%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Exelixis (EXEL) Tops Q4 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 46.67% and -0.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.

Exelixis (EXEL) Gains But Lags Market: What You Should Know

In the latest trading session, Exelixis (EXEL) closed at $17.60, marking a +0.69% move from the previous day.

Roche Submits Application for Tecentriq-Avastin Combo in HCC

Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.

GILD or EXEL: Which Is the Better Value Stock Right Now?

GILD vs. EXEL: Which Stock Is the Better Value Option?

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study

Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.

Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

A low-key week for the biotech sector, with a few pipeline and regulatory updates.

Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study

Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.

Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 55.00% and 18.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards?

Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q3 results.

Earnings Preview: Exelixis (EXEL) Q3 Earnings Expected to Decline

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study

Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

Seattle Genetics Up on Positive Data From Bladder Cancer Study

Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.

Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.

Ekta Bagri headshot

Renal Cell Carcinoma Space in Focus: Some Key Developments

The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.

Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales

Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.

Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines

Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.

Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 8.70% and 5.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?

Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.

Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

EXEL or ILMN: Which Is the Better Value Stock Right Now?

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

Key highlights of the past week include collaborations and other pipeline updates.